DAFTAR PUSTAKA

1.   Giugliano RP, Braunwald E. The year in acute coronary syndrome. Journal of the American College of Cardiology. 2014;63:201-14
2.   Ibanez B, James S, Agewall S, Antunes MJ, Ducci CB, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segmen elevation. Eropean Heart Journal. 2017:1-66
3.   RISKESDAS. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS). L nas. 2013:1-384
4.   Sadrnia S, Pourmoghaddas M, Hadizadeh M, Maghamimehr A, Esmaeeli M, Amipour A, et al. Factors affecting outcome of primary percutaneous coronary intervention for acute myocardial infarction. Arya Atherosclerotic. 2013;9:241-4
5.   Hosseiny AD, Moloi S, Chandrasekhar, Farshid A. Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. Open Heart. 2006;3:1-7
6.   Data dari Divisi Diagnostik Invasif Bagian Kardiologi RSUP. Dr. M. Djamil Padang
7.   Tedgui A. The role of inflammation in atherothrombosis: implication for clinical prcatice. Vascular medicine. 2005;10:45-53
8.   Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. Jornal of Geriatric Cardiology. 2015;12:305-12
9.   Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999;99:2503-9
10.   Meeuwsen JA, Wesseling M, Hoefer IE, Jager SC. Prognostic value of circulating inflammatory cells in patients with stable and acute coronary artery. Frontiers in cardiovascular medicine. 2017;4:44
11.   Mincu RI, Janosi RA, Vinereanu D, Rassaf T, Todzek M. Preprocedural C-Reactive protein predicts outcome after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction a systemic meta-analysis. Scientific reports. 2017:1-10
12.   Kafkas N, Venetsanou K, Patsilinakos S, Voudris V, Antonatos D, Kelesidis K, et al. Procalcitonin in acute myocardial infarction. Acute Cardiac Care. 2008;10:30-36
13.   Sinning CR, Sinning JM, Schulz A, Schnabel RB, Lubos E, Wild PS. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circulation Journal. 2011;75:1184-91
14.   Picariello C, Lazzeri C, Attana P, Chiostri M, Gensini GF, Valente S. The impact of admission procalcitonin on prognosis in acute coronary syndromes. Biomarkers. 2012;17:56-61

15. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43

16. Angiolillo DJ, Biasucci LM, Liuzzo GL, Crea F. Inflammation in acute coronary syndromes: mechanisms and clinical implications. Rev Eso Cardiol. 2004;57:433-46

17. Ross R. Atherosclerosis: an inflammatory disease. N Engl Journal Medicine. 1999;340:115-26

18. Idzkowska E, Eljaszewicz A, Miklasz P, Musial WJ, Tycinska AM, Moniuszko M. The role of different monocyte subsets in the pathogenesis of atherosclerosis and acute coronary syndromes. Scandinavian Journal of Immunology. 2015;82:163-73

19. Samara WM, Gurbel PA. The role of platelete receptors and adhesion molecules in coronary artery disease. Coronary Artery Disease. 2003;14:1047-54

20. Libby P, Theroux P. Basic Science for Clinicians Pathophysiology of Coronary Artery Disease The Pathophysiology of Chronic CAD. 2005:1-5

21. Libby P, Tabas I, Fredman G, Fisher E. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114:1867-79

22. Motoyama S, Kondo T, Sarai M, Suguira A, Harigaya H, Sato T, et al. Multislice computed tomographyc characteristics of coronary lesions in acute coronary syndromes. J am Coll Cardiol. 2007;50:319-26

23. Kataoka Y, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, et al. Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: Insight from serial intravascular ultrasound. J Am coll Cardiol. 2012; 59:1592-97

24. Libby P. Molecular bases of acute coronary syndrome. Circulation. 1995;91:2844-50

25. Libby P, Ridker PM. Inflammation and atherothrombosis from population biology and bench research to clinical practice. Journal of the American College of Cardiology. 2006;48:33-46

26. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. 1993;69:377-81

27. Picariello C, Lazzeri C, Chiostri M, Gensini G, Valente S. Procalcitonin in acute cardiac patients. Internal Emergency Medicine. 2011;6:245-52

28. Schiopu A, Hedblad B, Engstorm G, Struck J, Morgenthaler NG, Melander O, et al. Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study. Journal of internal medicine. 2012;272: 484-91

29. Meisner M. Update on procalcitonin measurements. Annals of laboratory medicine. 2014;34:263-73

30. Ertem AG, Efe TH, Yayla C, Akboga MK, Acar B, Unal S, et al. The Association between serum procalcitonin levels and severity of coronary artery disease assessed by SYNTAX score in patients with acute coronary syndrome. Angiology. 2016:1-5

31. Dandona P, Nix D, Wilson MF. Procalcitonin increase after endotoxin injection in normal subjects. Journal Clinical Endocrinol Metabolic. 1994;79:1605-8

32. Buratti T, Ricevuti G, Pechlaner C, Ioannidis M, Wiedermann F, Gritti D, et al. Plasma levels of procalcitonin and interleukin-6 in acute myocardial infarction. Inflammation. 2001;2:97-100

33. Remskar M, Horvat M, Hojker S, Noc M. Procalcitonin in patients with acute myocardial infarction. Wien Klin Wochenschr. 2002;114:205-10

34. Picariello C, Lazzeri C, Chiostri M, Gensini G, Valente S. Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention. Internal Emergency Medicine. 2009;4:403-8

35. Rahmani F, Rastian ML, Ghanbarzehi A, Behnammoghadam M, Abdollahimohammad A. Procalcitonin: a novel biomarker in coronary artery disease. Indian Journal of Fundamental and Applied Life Sciance. 2015;5:2887-93

36. Senturk T, Cordan J, Baran I, Ozdemir B, Gullulu S, Aydinlar A, et al. Procalcitonin in patients with acute coronary syndrome: correlation with high-sensitive C-reactive protein, prognosis and severity of coronary artery disease. Acta Cardiologica. 2007;62:135-41

37. Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanism, incidence and identification of patients at risk. World Journal of Cardiology. 2017;9:1-14

38. Hicks KA, Hung MJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridg NL, et al. ACC/AHA Key data elements and definitions for cardiovascular endpoint events in clinical trials. 2014:1-37

39. Kelly D, Khan SQ, Dhillon O, Quinn P, Struck J, Squire IB, et al. Procalcitonin as a prognostic marker in patients with acute myocardial infarction. Biomarkers. 2010;15:325-31

40. Ataoglu HE, Yilmaz F, Uzunhasan I, Cetin F, Temiz LU, Doventas YE, et al. Procalcitonin: A Novel Cardiac marker with prognostic value in acute coronary syndrome. Journal of International Medical Research. 2010;38:52-61

41. Patel T, George P. Serum procalcitonin: a novel biomarker in ST-segment elevation myocardial infarction to predict in-hospital and 30 days outcomes. JACC. 2016;67:503

42. Steyerberg EW. Clinical prediction models: a practical approach to development, validation and updating. Springer, USA. 2009

43. Sastroasmoro S, Ismael S. Dasar-dasar Metode Penelitian Klinis. Edisi 3. CV Sagung Seto. Jakarta. 2010

44. Malik N, Babu G, Davies JR. age related mortality of primary PCI patients at a high volume UK cardiac center. Heart. 201;98:28

45. Benamer H, Tafflet M, bataille S, Escolano S, Livarek B, et al. Female gender is an independent predictor of in-hospital mortality after STEMI in

the era of primary PCI: insight from the greater Paris area PCI registry. Eurointervention. 2011;6:1037-9

46. Guo Y, Yin F, Fan C, Wang Z. Gender difference in clinical outcomes of the patients with coronary artery disease after percutaneous coronary intervention: A systematic review and meta-analysis. Medicine. 2018;97:30

47. Gupta A, Verma SK, Sharma R, Parakh N, Ramakrishnan S, Roy A, et al. Clinical and angiographic profiles and six months outcomes of smokers with acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary angioplasty. Indian Heart Journal. 2018;70:680-4

48. Rakowski T, Siudak Z, Dziewierz A, Dubiel JS, Dudek D. Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Journal Thromb Thrombolysis. 2012;34:397-403

49. Cho JY, Jeong MH, Ahn Y, Hong YJ, Park HW, et al. High lipoprotein (a) levels are associated with long-term adverse outcomes in acute myocardial infarction patients in high killip classes. Korean Circulation Journal. 2010;40:491-8

50. Kazazi EH, Sheikhvatan M, Mahmoodian M, fathollahi M, Sadeghian H. Comparing angiography features of inferior versus myocardial infarction regarding severity and extension in a cohort of Iranian patients. Journal of Research in Medical Scienices. 2011;16:484-9

51. Nishi N, Naknishi N, Kuroda K, Koizumi K, Yoshikawa J, et al. Relationships of site of infarction and history of previous infarction with short- and long-term prognosis after acute myocardial infarction in japan. Journal Clinical Epidemiology. 1992;45:39-45

52. Weissler-Snir A, Gurevitz C, Assali A, Vaknin H, Bental T, Lador A, et al. Prognosis of STEMI patients with multi-vessel disease undergoing culprit-only PCI without significant residual ischemia on non-invasive stress testing. Plos One. 2015;10:e0138474

53. Hall TS, Hallen J, Krucoff MW, Roe MT, Brennan DM, atar D, et al. Cardiac troponin I for prediction of clinical outcomes and acrdiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. American Heart Journal. 2015;169:257-65

54. Vakili H, Sadeghi R, Rezapoor P, Gachkar L. In-hospital outcomes after primary percutaneous coronary intervention according to left ventricular ejection fraction. Arya Atherosclerotic. 2014;10:211-7

55. Mamas MA, Anderson SG, O'Kane PD, Keavney B, Nolan J, Oldroyd KG, et al. Impact of left ventricular function in relation to procedural outcomes following perutaneous coronary intervention: insight from the British Cardiovascular Intervention Society. European Heart Journal. 2014;35:3004-12

56. Dudek D, Dziewierz A, Rakowski T, El Masri N, Sorysz D, Zalewski J, et al. Time-to-reperfusion therapy influences outcome of patients with myocardial infarction subjected to facilitated PCI. Euro Intervention.

2005;1:309-14

57. Dai J, xia B, Wu X. Elevated plasma procalcitonin level predicts poor prognosis of ST elevation myocardial infarction in Asian elderly. Scandinavian Journal of Clinical and Laboratory Investigation. 2017;11:1-7